Barclays’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,326,600
| Closed | -$106M | – | 5432 |
|
|
2024
Q4 | $106M | Buy |
1,326,600
+523,400
| +65% | +$45.3M | 0.03% | 389 |
|
|
2024
Q3 | $72.3M | Buy |
+803,200
| New | +$67.6M | 0.02% | 549 |
|
|
2023
Q3 | – | Sell |
-79,200
| Closed | -$6.98M | – | 4661 |
|
|
2023
Q2 | $6.98M | Buy |
+79,200
| New | +$6.82M | ﹤0.01% | 1152 |
|
|
2022
Q1 | – | Sell |
-40,700
| Closed | -$4.21M | – | 5362 |
|
|
2021
Q4 | $4.21M | Buy |
40,700
+34,900
| +602% | +$4.04M | ﹤0.01% | 1834 |
|
|
2021
Q3 | $727K | Hold |
5,800
| – | – | ﹤0.01% | 2978 |
|
|
2021
Q2 | $720K | Hold |
5,800
| – | – | ﹤0.01% | 2866 |
|
|
2021
Q1 | $685K | Sell |
5,800
-282,800
| -98% | -$33.1M | ﹤0.01% | 3002 |
|
|
2020
Q4 | $33.8M | Buy |
288,600
+154,100
| +115% | +$17M | 0.02% | 587 |
|
|
2020
Q3 | $14M | Buy |
134,500
+13,000
| +11% | +$1.31M | 0.01% | 888 |
|
|
2020
Q2 | $11.1M | Sell |
121,500
-215,800
| -64% | -$20.7M | 0.01% | 907 |
|
|
2020
Q1 | $30.4M | Buy |
337,300
+249,000
| +282% | +$26.5M | 0.02% | 476 |
|
|
2019
Q4 | $10M | Sell |
88,300
-7,700
| -8% | -$845K | 0.01% | 1397 |
|
|
2019
Q3 | $10.4M | Sell |
96,000
-168,700
| -64% | -$17.6M | 0.01% | 1253 |
|
|
2019
Q2 | $25.8M | Buy |
264,700
+65,100
| +33% | +$5.94M | 0.02% | 794 |
|
|
2019
Q1 | $18.2M | Sell |
199,600
-98,300
| -33% | -$8.8M | 0.01% | 903 |
|
|
2018
Q4 | $27.1M | Sell |
297,900
-31,100
| -9% | -$2.91M | 0.02% | 616 |
|
|
2018
Q3 | $32.4M | Sell |
329,000
-49,100
| -13% | -$4.54M | 0.02% | 612 |
|
|
2018
Q2 | $32.4M | Sell |
378,100
-69,600
| -16% | -$5.81M | 0.03% | 551 |
|
|
2018
Q1 | $35.9M | Sell |
447,700
-47,100
| -10% | -$3.88M | 0.03% | 558 |
|
|
2017
Q4 | $40M | Sell |
494,800
-266,900
| -35% | -$21.4M | 0.03% | 491 |
|
|
2017
Q3 | $59.2M | Buy |
761,700
+411,100
| +117% | +$34.1M | 0.06% | 252 |
|
|
2017
Q2 | $31.1M | Sell |
350,600
-50,300
| -13% | -$4.24M | 0.03% | 426 |
|
|
2017
Q1 | $32.3M | Buy |
400,900
+172,130
| +75% | +$13.4M | 0.04% | 377 |
|
|
2016
Q4 | $16.3M | Buy |
228,770
+33,400
| +17% | +$2.62M | 0.02% | 690 |
|
|
2016
Q3 | $16.9M | Sell |
195,370
-370,300
| -65% | -$32.3M | 0.02% | 618 |
|
|
2016
Q2 | $49.1M | Buy |
565,670
+243,900
| +76% | +$19.7M | 0.06% | 263 |
|
|
2016
Q1 | $24.1M | Buy |
321,770
+79,445
| +33% | +$5.98M | 0.04% | 417 |
|
|
2015
Q4 | $18.4M | Buy |
242,325
+4,200
| +2% | +$316K | 0.02% | 609 |
|
|
2015
Q3 | $15.7M | Sell |
238,125
-184,585
| -44% | -$13.6M | 0.02% | 708 |
|
|
2015
Q2 | $31.3M | Buy |
422,710
+209,340
| +98% | +$16M | 0.04% | 452 |
|
|
2015
Q1 | $16.4M | Buy |
213,370
+57,570
| +37% | +$4.36M | 0.02% | 800 |
|
|
2014
Q4 | $11.2M | Sell |
155,800
-690,400
| -82% | -$48M | 0.01% | 1106 |
|
|
2014
Q3 | $51.6M | Buy |
846,200
+774,400
| +1,079% | +$49.2M | 0.05% | 314 |
|
|
2014
Q2 | $4.52M | Sell |
71,800
-16,100
| -18% | -$978K | ﹤0.01% | 1838 |
|
|
2014
Q1 | $5.36M | Buy |
87,900
+6,200
| +8% | +$361K | 0.01% | 1648 |
|
|
2013
Q4 | $4.66M | Sell |
81,700
-76,200
| -48% | -$4.32M | ﹤0.01% | 1885 |
|
|
2013
Q3 | $8.37M | Sell |
157,900
-28,700
| -15% | -$1.54M | 0.01% | 1281 |
|
|
2013
Q2 | $9.6M | Buy |
+186,600
| New | +$9.22M | 0.01% | 1102 |
|
Other funds holding MDT
VCM
VPM
Barclays's MDT Position: Q1 2026 in Review
Barclays increased its Medtronic (MDT) stake by 23% in Q1 2026, buying an estimated $49.3M and bringing the position to 2,755,141 shares worth $239M. The position accounts for 0.06% of the portfolio, ranked #251.
Barclays first reported a position in MDT in Q2 2013 and has held it in 52 quarters since. The position peaked at $904M in Q2 2022. 2,231 funds tracked by Wall St. Rank hold MDT as of Q1 2026.
- Barclays held 2,755,141 shares of Medtronic worth $239M as of Q1 2026.
- Barclays bought 514,177 Medtronic shares in Q1 2026, an estimated $49.3M.
- Medtronic made up 0.06% of Barclays's portfolio in Q1 2026, its #251 holding.
- Barclays first reported a position in Medtronic in Q2 2013 and has held it in 52 quarters since.
- Barclays's Medtronic position peaked at $904M in Q2 2022.
- 2,231 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.